Clinical

Dataset Information

0

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT


ABSTRACT: Primary objectives: To demonstrate that the combination of FOLFIRI plus sunitinib is superior to FOLFIRI plus placebo in prolonging the progression-free survival (PFS) in the first-line treatment of patients with metastatic colorectal cancer. Primary endpoints: Progression-free survival (PFS)

DISEASE(S): Metastatic Colorectal Cancer,First-line Treatment Of Patients With Metastatic Colorectal Cancer.

PROVIDER: 2521530 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2015-06-26 | GSE70282 | GEO
2015-06-26 | E-GEOD-70282 | biostudies-arrayexpress
| 2528184 | ecrin-mdr-crc
| 2528754 | ecrin-mdr-crc
2024-08-26 | GSE275628 | GEO
2013-01-15 | E-MTAB-951 | biostudies-arrayexpress
2016-07-06 | E-MTAB-4881 | biostudies-arrayexpress
2016-08-01 | E-GEOD-65021 | biostudies-arrayexpress
2015-12-17 | E-GEOD-76068 | biostudies-arrayexpress
2015-12-17 | GSE76068 | GEO